Clinical Trial

TPAD for Recovery of Standing After Severe SCI

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate how standing and sitting balance control is altered after spinal cord injury (SCI) and how a new type of robotic assistive device may be used to improve muscle function. This device is called the Tethered Pelvic Assist Device, or TPAD. The main aims are to: 1\. Examine muscle activation patterns generated during different types of standing in spinal cord injured individuals using robotic assistance or self-assistance for balance 2 and 3. Examine the effectiveness of robotic-assisted stand training in the improvement of posture control during different types of standing and sitting in spinal cord injured individuals. Participants will be placed into one of 5 groups based on a physical classification of their spinal cord injury: Group 1: * Individuals with SCI that can stand independently * Will receive TPAD training * Will undergo standing, posture, sitting, and stepping assessments * Participation in this group will last about six months Group 2: * Individuals with SCI that cannot stand independently * Will receive TPAD training * Will undergo standing, posture, sitting, and stepping assessments * Participation in this group will last about 6 months Group 3: * Individuals with SCI that can stand independently * Will undergo standing and posture assessments * Participation in this group will last about 2 weeks Group 4: * Individuals with SCI that cannot stand independently * Will undergo standing and posture assessments * Participation in this group will last about 2 weeks Group 5: * Individuals without a SCI * Will undergo standing, posture, and sitting assessments * Participation in this group will last about 2 weeks
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-14.
Trial Details
NCT Number NCT06643312
Lead Sponsor Kessler Foundation
Conditions SCI - Spinal Cord Injury
Enrollment 50 participants
Start Date 2024-10-22
Primary Completion 2027-10 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-16